Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study

OBJECTIVE: Patients with metastatic colorectal cancer (mCRC) had oncological benefits with irinotecan dose escalation of FOLFIRI regimen combined with bevacizumab according to UGT1A1 genotypes in our previous study. In the current study, we performed a quality of life (QOL) outcome evaluation and co...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Hon-Yi, Chen, Yen-Cheng, Huang, Ching-Wen, Li, Ching-Chun, Su, Wei-Chih, Chang, Tsung-Kun, Chen, Po-Jung, Yin, Tzu-Chieh, Tsai, Hsiang-Lin, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964058/
https://www.ncbi.nlm.nih.gov/pubmed/35359363
http://dx.doi.org/10.3389/fonc.2022.756078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964058/
https://www.ncbi.nlm.nih.gov/pubmed/35359363
http://dx.doi.org/10.3389/fonc.2022.756078

Ejemplares similares